LONDON, March 22 (Reuters) - GlaxoSmithKline PLC:
* Announces Swiss approval of duodart
* Significant milestone for duodart, as it is the first approval in Europe
* The first fixed dose combination medicine for benign prostatic hyperplasia
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces Swiss approval of duodart
* Significant milestone for duodart, as it is the first approval in Europe
* The first fixed dose combination medicine for benign prostatic hyperplasia
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.